Evaluating the Therapeutic Potential of Ublituximab in the Treatment of MS: Design, Development and Place in Therapy
Drug Design, Development and Therapy · 2024-07 · Volume 18 · 3025-3042
DOI: 10.2147/dddt.s388410 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2024-07. Verfasst von Sarah-Jane Martin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurology, Department of Medicine, St Michael's Hospital, Toronto, Canada. Hauptthemen laut MEDLINE: Multiple Sclerosis, Antibodies, Monoclonal. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Neurology, Department of Medicine, St Michael's Hospital, Toronto, Canada.
- University of Glasgow, Glasgow, UK.
ORCID-Profile: Sarah-Jane Martin
Zitieren
APA
Martin, S. J., Guenette, M., & Oh, J. (2024). Evaluating the Therapeutic Potential of Ublituximab in the Treatment of MS: Design, Development and Place in Therapy. Drug Design, Development and Therapy, Volume 18, 3025-3042. https://doi.org/10.2147/dddt.s388410
Vancouver
Martin SJ, Guenette M, Oh J. Evaluating the Therapeutic Potential of Ublituximab in the Treatment of MS: Design, Development and Place in Therapy. Drug Design, Development and Therapy. 2024;Volume 18:3025-3042. doi:10.2147/dddt.s388410
BibTeX
@article{Martin2024,
author = {Martin, Sarah-Jane and Guenette, Melanie and Oh, Jiwon},
title = {Evaluating the Therapeutic Potential of Ublituximab in the Treatment of MS: Design, Development and Place in Therapy},
journal = {Drug Design, Development and Therapy},
year = {2024},
volume = {Volume 18},
pages = {3025--3042},
doi = {10.2147/dddt.s388410}
}
EUVIMED